US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Xtrackers Nifty 500 India ETF

23.15

-0.0133-0.06%

Volume:494

Turnover:11.43K

Market Cap:4.63M

PE:- -

High:23.15

Open:23.12

Low:23.12

Close:23.16

52wk High:27.40

52wk Low:20.52

Shares:200.00K

Float Shares:200.00K

Volume Ratio:0.63

T/O Rate:0.25%

Dividend:0.08

Dividend Rate:0.34%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

HAIXI PHARMA Advances Oral nAMD Treatment with FDA Trial Approval and New Chinese Study

CARsgen Therapeutics Receives China IND Clearance for Multiple Myeloma Therapy; Shares Up 3%

MT Newswires Live

Caliway Biopharma Submits China Phase 1 IND for CBL-514 Fat-Reduction Drug

MT Newswires Live

India Ratings Affirms JSW Renew Energy Ten's 'IND A/Stable' Rating

MT Newswires Live

China's Nod Granted to CARSGEN-B's BCMA-Targeting Universal CAR-T for Hard-to-Treat Myeloma

Press Release: Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody IND Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise

LEADS BIOLABS-B shares climb nearly 6% as PD-L1/4-1BB bispecific antibody gets IND clearance for advanced colorectal cancer treatment

InSilico Medicine Wins China IND for AI-Designed Parkinson’s Drug

Nanjing Leads Biolabs Wins IND Nod for Bispecific Antibody in Metastatic Colorectal Cancer

India's Capital Attraction Strategies Garner Over $40 Billion in Foreign Investment

Indian equities rebound after AI-driven selloff; IT stocks surge while banking, power, and pharma sectors attract investment

Neurotech secures FDA IND nod and U.S. patent wins as autism drug program advances

Press Release: Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update

MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies

Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/IND/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","market":"US","secType":"STK","nameCN":"Xtrackers Nifty 500 India ETF","latestPrice":23.145,"timestamp":1788206400000,"preClose":23.1583,"halted":0,"volume":494,"delay":0,"changeRate":-0.0005743081314259241,"floatShares":200001,"shares":200001,"eps":0,"marketStatus":"Pre-Mkt","change":-0.0133,"latestTime":"09-01 05:13:15 EDT","open":23.115,"high":23.145,"low":23.115,"amount":11430,"amplitude":0.001295,"askPrice":24,"askSize":19,"bidPrice":9.31,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788269400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":23.145,"sharesOutstanding":200001,"nav":23.107,"aum":4621406.79,"dividendRate":0.003409,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":23.115,"preClose":23.145,"latestTime":"16:10 EDT","volume":7,"amount":162.015,"timestamp":1788207004404,"change":-0.03,"changeRate":-0.001296,"amplitude":0},"volumeRatio":0.6283389809433055},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","floatShares":200001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.6283389809433055,"shares":200001,"dividePrice":0.0789,"high":23.145,"amplitude":0.001295,"preClose":23.1583,"low":23.115,"week52Low":20.515,"pbRate":"--","week52High":27.4,"institutionHeld":0,"latestPrice":23.145,"committee":0.680672,"eps":0,"divideRate":0.003409,"volume":494,"delay":0,"ttmEps":0,"open":23.115,"prevYearClose":24.78,"prevWeekClose":23.1583,"prevMonthClose":23.145,"prevQuarterClose":22.88,"fiveDayClose":23.065,"twentyDayClose":23.01,"sixtyDayClose":22.2234},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND\",params:#limit:5,,,undefined,":[{"date":"2026-06-18","symbol":"IND","amount":0.07775,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-18","defaultRemindTime":1781789400000,"name":"Xtrackers Nifty 500 India ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-18","currency":"USD","dateTimestamp":1781755200000,"payDate":"2026-06-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND\",market:\"US\",,,undefined,":[{"executeDate":"2026-06-18","recordDate":"2026-06-18","paymentDate":"2026-06-26","value":0.07775,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IND\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657831567","title":"Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657831567","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657831567?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:01","pubTimestamp":1785873660,"startTime":"0","endTime":"0","summary":"– Total revenue of $73 million in 2Q26, a 92% year-over-year increase – – Revuforj (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase – – Niktimvo (axatilimab-csfr) net re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338782/0/en/Syndax-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MF","BK4134","BK4113","BK4539","BK4563","IND","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656558343","title":"Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656558343","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656558343?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:00","pubTimestamp":1785841200,"startTime":"0","endTime":"0","summary":"Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients in P","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338130/0/en/Beam-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Announces-First-Patient-Dosed-in-Global-Pivotal-Cohort-of-BEAM-302-Trial-in-Alpha-1-Antitrypsin-Deficiency-AATD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4556","BK4588","LU1861558580.USD","LU1861559042.SGD","BK4505","BK4139","SCD","IDNA","BEAM","IND","BK4585","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157694686","title":"HAIXI PHARMA Advances Oral nAMD Treatment with FDA Trial Approval and New Chinese Study","url":"https://stock-news.laohu8.com/highlight/detail?id=1157694686","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157694686?lang=en_us&edition=fundamental","pubTime":"2026-08-04 17:20","pubTimestamp":1785835221,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) announced that the U.S. Investigational New Drug (IND) application for its internally developed drug candidate, HX9428, has been approved by the U.S. Food and Drug Administration...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDTX","BK4588","BK1191","BMED","IBBQ","IND","PSYK","BK4585","LABU","02637","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656958065","title":"CARsgen Therapeutics Receives China IND Clearance for Multiple Myeloma Therapy; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656958065","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656958065?lang=en_us&edition=fundamental","pubTime":"2026-08-04 14:30","pubTimestamp":1785825028,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics' (HKG:2171) CT0596 obtained investigational new drug clearance from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.Shares of the b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK1585","BK4139","BK4007","BK1574","02171","BK1587","IND","BK1161","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656261587","title":"Caliway Biopharma Submits China Phase 1 IND for CBL-514 Fat-Reduction Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2656261587","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656261587?lang=en_us&edition=fundamental","pubTime":"2026-08-04 14:19","pubTimestamp":1785824364,"startTime":"0","endTime":"0","summary":"Caliway Biopharmaceuticals  submitted an investigational new drug  application to China's National Medical Products Administration's Center for Drug Evaluation for a phase one study of abdominal fact reduction drug.The CBL-0102 trial will evaluate the safety, tolerability and pharmacokinetic profile of CBL-514 in about 30 healthy Chinese subjects, following completion of a pre-IND meeting with the regulator.The company said the localized phase 1 study will assess potential racial differences in the drug's efficacy and safety between Chinese and non-Chinese populations, with a China phase 3 application planned after the phase 1 study is completed.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4080","BK7095","IND","BK4231","CBL","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656581285","title":"India Ratings Affirms JSW Renew Energy Ten's 'IND A/Stable' Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2656581285","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656581285?lang=en_us&edition=fundamental","pubTime":"2026-08-04 12:13","pubTimestamp":1785816816,"startTime":"0","endTime":"0","summary":"JSW Energy  said India Ratings and Research affirmed the \"IND A/Stable/IND A1\" rating on the bank loan facilities of JSW Renew Energy Ten, a step-down wholly owned subsidiary of the company, according to a Monday exchange filing.The rating agency reaffirmed the rating for the subsidiary's bank loan facilities in a release dated Aug. 3, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IND","MNDmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151736677","title":"China's Nod Granted to CARSGEN-B's BCMA-Targeting Universal CAR-T for Hard-to-Treat Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=1151736677","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151736677?lang=en_us&edition=fundamental","pubTime":"2026-08-04 08:14","pubTimestamp":1785802452,"startTime":"0","endTime":"0","summary":"CARSGEN-B (02171) has announced that its universal CAR-T cell product, CT0596, which targets BCMA, has received Investigational New Drug (IND) approval from China's National Medical Products...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1587","BK1585","BK1574","IND","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656379644","title":"Press Release: Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2656379644","media":"Dow Jones","labels":["executive","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656379644?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:30","pubTimestamp":1785760200,"startTime":"0","endTime":"0","summary":"BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUE","NVIB","BK4139","IND","BK4022","BK4232","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656321081","title":"Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses","url":"https://stock-news.laohu8.com/highlight/detail?id=2656321081","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656321081?lang=en_us&edition=fundamental","pubTime":"2026-08-03 16:00","pubTimestamp":1785744000,"startTime":"0","endTime":"0","summary":"The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privosegtor in acute multiple sclerosis (MS) relapses, addressing a significant unmet medical needThe FDA c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337249/0/en/Oculis-Announces-Positive-FDA-Pre-IND-Feedback-Supporting-Privosegtor-Development-Strategy-for-Treatment-of-Acute-Multiple-Sclerosis-Relapses.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4512","LU2111349929.HKD","LU0557290698.USD","RGC","ON","BK4516","LU1978683503.SGD","REM","LU0724618433.USD","IE00B3S45H60.SGD","LU0098860793.USD","IAI","LU1854103824.USD","LU1989772840.SGD","LU0053666078.USD","KBWB","LU2347655156.SGD","LU0106831901.USD","BK4110","BK4581","EMA","LU2133065610.SGD","BK4534","LU1791710400.SGD","LU0795875169.SGD","LU2271345857.HKD","BK4605","LU2089284900.SGD","LU2360107325.USD","ARR","LU0006306889.USD","BK4127","LU0106261372.USD","BK4081","LU2298322129.HKD","LU1363072403.SGD","LU2023251221.USD","IE00BZ1G4Q59.USD","LU1244550577.SGD","MORT","LU1791710582.SGD","LU1074936037.SGD","OCS","LU1988902786.USD","LU2487616109.SGD","LU1861220033.SGD","IND","IE00BFMHRM44.USD","LU0158827781.USD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656134744","title":"Leads Biolabs' PD-L1/4-1BB Bispecific Antibody IND Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise","url":"https://stock-news.laohu8.com/highlight/detail?id=2656134744","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656134744?lang=en_us&edition=fundamental","pubTime":"2026-08-03 11:43","pubTimestamp":1785728580,"startTime":"0","endTime":"0","summary":"NANJING, China, Aug.  02, 2026  (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the Center for Drug Evaluation (CDE) of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337201/0/en/Leads-Biolabs-PD-L1-4-1BB-Bispecific-Antibody-IND-Application-for-Combination-Therapy-in-Metastatic-Colorectal-Cancer-Approved-Further-Strengthening-Gastrointestinal-Oncology-Franc.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRC","GDXJ","YBTC","CBTO","ODD","XBTY","BTCL","EZBC","PD","BITY","BITO","BFJL","DEFI","QBF","BTCZ","HCC","MAXI","OC","IDNA","IND","SIL","CBOA","MNRS","XME","BITI","BCCC","BTCO","CBXO","SGDM","BETH","COAL","CBXY","BTCI","FBTC","BRRR","BTRN","CBXJ","CBXA","CBTJ","BITX","ARKB","BITU","CBTA","MSS","BTC","XHB","CDE","BTCW","HODL","CBOJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122893332","title":"LEADS BIOLABS-B shares climb nearly 6% as PD-L1/4-1BB bispecific antibody gets IND clearance for advanced colorectal cancer treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1122893332","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122893332?lang=en_us&edition=fundamental","pubTime":"2026-08-03 10:32","pubTimestamp":1785724340,"startTime":"0","endTime":"0","summary":"Shares of LEADS BIOLABS-B (09887) rose nearly 6% in early trading, last up 5.71% at HK$56.45 with a turnover of HK$75.0476 million.On August 3, the company announced that China's National Medical...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","VXUS","BK1161","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","BK4585","KCAI","09887","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656349689","title":"InSilico Medicine Wins China IND for AI-Designed Parkinson’s Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2656349689","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656349689?lang=en_us&edition=fundamental","pubTime":"2026-08-03 08:38","pubTimestamp":1785717492,"startTime":"0","endTime":"0","summary":"The latest announcement is out from InSilico Medicine Cayman TopCo ( ($HK:3696) ). InSilico Medicine has secured investigational new drug approval ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/insilico-medicine-wins-china-ind-for-ai-designed-parkinsons-drug?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/insilico-medicine-wins-china-ind-for-ai-designed-parkinsons-drug?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VTHR","PSIL","TBXU","CHAT","QTOC","AIPO","ARTY","AGIX","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656034545","title":"Nanjing Leads Biolabs Wins IND Nod for Bispecific Antibody in Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2656034545","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656034545?lang=en_us&edition=fundamental","pubTime":"2026-08-03 06:37","pubTimestamp":1785710242,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. Class H ( ($HK:9887) ) has shared an update. Nanjing Leads Biolabs has received approval from China’s National Medi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nanjing-leads-biolabs-wins-ind-nod-for-bispecific-antibody-in-metastatic-colorectal-cancer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nanjing-leads-biolabs-wins-ind-nod-for-bispecific-antibody-in-metastatic-colorectal-cancer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161318466","title":"India's Capital Attraction Strategies Garner Over $40 Billion in Foreign Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=1161318466","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161318466?lang=en_us&edition=fundamental","pubTime":"2026-08-01 13:40","pubTimestamp":1785562857,"startTime":"0","endTime":"0","summary":"India has been actively courting overseas capital, attracting over $40 billion since June to bolster the central bank's foreign exchange reserves.With global crude oil prices rising, Indian...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDE","SMIN","GIND","NDIA","FLIN","NFTY","EPI","INDL","INDA","INQQ","IND","PIN","BK4585","MNDmain","IOPP","SCIN","FLIBF","INCO","BK4523","IMVP","INDY","BK4588","TAJX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150288494","title":"Indian equities rebound after AI-driven selloff; IT stocks surge while banking, power, and pharma sectors attract investment","url":"https://stock-news.laohu8.com/highlight/detail?id=1150288494","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150288494?lang=en_us&edition=fundamental","pubTime":"2026-07-31 13:48","pubTimestamp":1785476912,"startTime":"0","endTime":"0","summary":"Global turbulence surrounding artificial intelligence has triggered a sharp rebound in Indian equities, with the Nifty IT index surging nearly 19% in July.India's second-largest asset manager, ICICI...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KEMX","MEM","BK1574","INDA","SPEM","INDE","BK4523","IOPP","SCHE","AEF","QEMM","BCHI","GIND","EPI","09939","XC","STXE","VGT","XXCH","BKEM","ASIA","INDL","XSOE","159938","EMXC","VEU","NDIA","QTOC","XCEM","PEMX","GLIN","EEMV","EET","DEXC","IMVP","HEEM","CHAT","161121","EEMA","EQLT","INDZ","AGIX","DFAE","BK4585","BK1161","PIN","BK4588","INDQ","FLIBF","INQQ","VEXC","FEMR","RWEM","VTHR","QLVE","IND","XCNY","INDY","MEMX","159146","INDH","BKF","SCIN","BBEM","MFEM","NFTY","TAJX","AIPO","TEMR","TEMX","ARTY","AVEM","EMES","INCO","BK4550","SMIN","BK1515","RAYE","FLIN","SEEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655338251","title":"Neurotech secures FDA IND nod and U.S. patent wins as autism drug program advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2655338251","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655338251?lang=en_us&edition=fundamental","pubTime":"2026-07-31 09:17","pubTimestamp":1785460678,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Neurotech International ( ($AU:NTI) ). Neurotech International’s June-quarter activities centred on advancing N...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurotech-secures-fda-ind-nod-and-u-s-patent-wins-as-autism-drug-program-advances?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurotech-secures-fda-ind-nod-and-u-s-patent-wins-as-autism-drug-program-advances?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","USRD","LABU","BK4585","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655872868","title":"Press Release: Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2655872868","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655872868?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412800,"startTime":"0","endTime":"0","summary":"greatest potential for success. The strategy concentrates resources on. blarcamesine across three CNS indications: early Alzheimer's disease and. Rett syndrome, where the Company's clinical and regulatory foundation is. most advanced, and Fragile X, where FDA Orphan Drug Designation,supportive preclinical and biomarker data, and the absence of any. approved therapy may lead to a promising regulatory path with the FDA.Alzheimer's Disease Program-- At the end of March 2026, the Company opened an Investigational New Drug.  application for early Alzheimer's disease with the FDA. This is an. important milestone: the IND enables clinical studies to be conducted in. the U.S. and provides the basis for substantive discussions with the FDA. to align on the Company's future clinical development for early. -- Two foundational clinical pharmacology studies are proceeding","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4085","LU1878469433.USD","AAIC","BK4022","SOCL","BK4135","BK4081","BK4097","IND","LABU","ADME","BK4139","R","BK4087","CHMP","CNS","EMA","BK4110","BK4585","BK4588","RPD","AVXL","BK4232","DDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655687216","title":"MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2655687216","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655687216?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412800,"startTime":"0","endTime":"0","summary":"Completion of 7-Day Toxicology and Pharmacokinetic Studies Advances Non-Opioid Pain Therapy and Obesity Candidate DevelopmentMIAMI, July  30, 2026  (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/30/3335999/0/en/MIRA-Pharmaceuticals-Progresses-MIRA-55-and-SKNY-1-Toward-IND-Enabling-Studies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B1BXHZ80.USD","LU0971096721.USD","BK4006","IE00BHPRN162.USD","LU2237443622.USD","MIRA","LU1363072403.SGD","IE00BKVL7J92.USD","LU2237443978.SGD","DEA","LU2237443465.HKD","IE00BZ1G4Q59.USD","LU2237443549.SGD","LU2237443382.USD","LU0267386448.USD","BK4007","LU0170899867.USD","LU2746668974.SGD","CMC","LU0149725797.USD","IND","BK4223","IE00BFXG1179.USD","BK4194","LU0882574139.USD","LU2237443895.HKD","LU2746668461.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655872437","title":"Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2655872437","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655872437?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:35","pubTimestamp":1785411300,"startTime":"0","endTime":"0","summary":"Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients CR-00","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/30/3335951/0/en/Crescent-Biopharma-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4581","ORR","IND","BK4585","BK4588","XBI","PFS","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655811687","title":"Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2655811687","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655811687?lang=en_us&edition=fundamental","pubTime":"2026-07-30 04:30","pubTimestamp":1785357000,"startTime":"0","endTime":"0","summary":"- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment o","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/29/3335623/0/en/Dyne-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","NVIB","MEDX","HYLG","BK4139","IND","BK4585","GDOC","BK4135","IDNA","DYN","BK4505","REC","BK4588","LABU","BMED"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}